Giritharan Suresh, Salhiyyah Kareem, Tsang Geoffrey M, Ohri Sunil K
Wessex Cardiac Centre, University Hospitals Southampton, Tremona Road, Southampton, SO16 6YD, UK.
, Southampton, UK.
J Cardiothorac Surg. 2018 Jun 15;13(1):68. doi: 10.1186/s13019-018-0745-2.
To assess the feasibility and efficacy of PuraStat®, a novel haemostatic agent, in achieving suture line haemostasis in a wide range of cardiac surgical procedures and surgery of the thoracic aorta.
A prospective, non-randomised study was conducted at our institution. Operative data on fifty consecutive patients undergoing cardiac surgery where PuraStat® was utilised in cases of intraoperative suture line bleeding was prospectively collected. Questionnaires encompassing multiple aspects of the ease of use and efficacy of PuraStat® were completed by ten surgeons (five consultants and five senior registrars) and analysed to gauge the performance of the product.
No major adverse cardiac events were reported in this cohort. Complications such as atrial fibrillation, pacemaker requirement and pleural effusions were comparable to the national average. Mean blood product use of packed red cells, platelets, fresh-frozen plasma (FFP) and cryoprecipitate was below the national average. There was one incidence of re-exploration, however this was due to pericardial constriction rather than bleeding. Analysis of questionnaire responses revealed that surgeons consistently rated PuraStat® highly (between a score of 7 and 10 in the various subcategories). The transparent nature or PuraStat® allowed unobscured visualisation of suture sites and possessed excellent qualities in terms of adherence to site of application. The application of PuraStat® did not interfere with the use of other haemostatic agents or manipulation of the suture site by the surgeon.
PuraStat® is an easy-to-use and effective haemostatic agent in a wide range of cardiac and aortic surgical procedures.
评估新型止血剂PuraStat®在广泛的心脏外科手术和胸主动脉手术中实现缝合线止血的可行性和有效性。
在我们机构进行了一项前瞻性、非随机研究。前瞻性收集了连续50例接受心脏手术患者的手术数据，这些患者在术中缝合线出血时使用了PuraStat®。由10名外科医生（5名顾问医生和5名高级住院医生）完成了涵盖PuraStat®易用性和有效性多个方面的问卷，并进行分析以评估该产品的性能。
该队列中未报告重大不良心脏事件。心房颤动、起搏器需求和胸腔积液等并发症与全国平均水平相当。浓缩红细胞、血小板、新鲜冰冻血浆（FFP）和冷沉淀的平均血制品使用量低于全国平均水平。有1例再次手术，然而这是由于心包缩窄而非出血。对问卷回复的分析显示，外科医生一直对PuraStat®评价很高（在各个子类别中得分在7到10分之间）。PuraStat®的透明性质使缝合部位可视化不受阻碍，并且在粘附于应用部位方面具有优异的品质。PuraStat®的应用不干扰其他止血剂的使用或外科医生对缝合部位的操作。
PuraStat®在广泛的心脏和主动脉外科手术中是一种易于使用且有效的止血剂。
